1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPhase 1 Exploratory/Developmental Grant (R61) is sponsored by National Institutes of Health (NIH). Supports the first phase of exploratory and developmental research projects, providing larger budgets and project periods.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Phase 1 Exploratory/Developmental Grant (R61) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Phase 1 Exploratory/Developmental Grant (R61) As part of a bi-phasic approach to funding exploratory and/or developmental research, the R61 provides support for the first phase of the award.
This activity code is used in lieu of the R21 activity code when larger budgets and/or project periods are required to establish feasibility for the project. Find ICO Specific Information Funding Considerations and Standard Due Dates apply.
AIDS and AIDS-Related Applications Beginning with applications for Advisory Council Review in January 2027 (i.e., application due dates on or after May 25, 2026), NIH will no longer accept applications submitted on dedicated AIDS application due dates. ( NOT-OD-26-029 ) Standard Application Due Dates (when applicable) Participating Funding Organizations Each funding opportunity specifies the participating organizations.
Applications must fit within the mission of at least one participating funding organization and meet all opportunity-specific requirements. The following funding organizations participate on at least one active funding opportunity.
Eunice Kennedy Shriver National Institute of Child Health and Human Development National Cancer Institute National Center for Complementary and Integrative Health National Heart, Lung, and Blood Institute National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Institute on Aging National Institute on Alcohol Abuse and Alcoholism Office of Research on Women's Health For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: U.S. domestic institutions; researchers proposing exploratory or developmental projects. Confirm the full requirements in the official notice before applying.
Phase 1 Exploratory/Developmental Grant (R61) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article